Pharmacogenomics in lung cancer chemotherapy

A review of what the oncologist should know

Chiara D'Antonio, Annalisa Milano, Riccardo Righini, Concetta Elisa Onesti, Maria Bassanelli, Rosa Falcone, Ida Paris, Salvatore Lauro, Paolo Marchetti

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Lung cancer is the leading cause of cancer-related death around the world; the addition of chemotherapy to treatment of this disease has been shown to significantly increase progression-free survival and overall survival. Despite newer chemotherapies, it is important to personalize the care (treatment and dose) upon each single patient's susceptibility for controlling and reducing adverse side-effects, at best. The present review describes the current status of pharmacogenomics studies regarding germline DNA variants that may alter response and tolerability to chemotherapeutic agents used to treat lung cancer, including perspective studies.

Original languageEnglish
Pages (from-to)5241-5250
Number of pages10
JournalAnticancer Research
Volume34
Issue number10
Publication statusPublished - Oct 1 2014

Fingerprint

Pharmacogenetics
Lung Neoplasms
Drug Therapy
Disease-Free Survival
Survival
DNA
Therapeutics
Neoplasms
Oncologists
Pharmacogenomic Testing

Keywords

  • Cisplatin
  • Gemcitabine
  • Lung cancer chemotherapy
  • Pemetrexed
  • Pharmacogenomic
  • Polymorphism patents
  • Taxanes
  • Vinorelbine

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Medicine(all)

Cite this

D'Antonio, C., Milano, A., Righini, R., Onesti, C. E., Bassanelli, M., Falcone, R., ... Marchetti, P. (2014). Pharmacogenomics in lung cancer chemotherapy: A review of what the oncologist should know. Anticancer Research, 34(10), 5241-5250.

Pharmacogenomics in lung cancer chemotherapy : A review of what the oncologist should know. / D'Antonio, Chiara; Milano, Annalisa; Righini, Riccardo; Onesti, Concetta Elisa; Bassanelli, Maria; Falcone, Rosa; Paris, Ida; Lauro, Salvatore; Marchetti, Paolo.

In: Anticancer Research, Vol. 34, No. 10, 01.10.2014, p. 5241-5250.

Research output: Contribution to journalArticle

D'Antonio, C, Milano, A, Righini, R, Onesti, CE, Bassanelli, M, Falcone, R, Paris, I, Lauro, S & Marchetti, P 2014, 'Pharmacogenomics in lung cancer chemotherapy: A review of what the oncologist should know', Anticancer Research, vol. 34, no. 10, pp. 5241-5250.
D'Antonio C, Milano A, Righini R, Onesti CE, Bassanelli M, Falcone R et al. Pharmacogenomics in lung cancer chemotherapy: A review of what the oncologist should know. Anticancer Research. 2014 Oct 1;34(10):5241-5250.
D'Antonio, Chiara ; Milano, Annalisa ; Righini, Riccardo ; Onesti, Concetta Elisa ; Bassanelli, Maria ; Falcone, Rosa ; Paris, Ida ; Lauro, Salvatore ; Marchetti, Paolo. / Pharmacogenomics in lung cancer chemotherapy : A review of what the oncologist should know. In: Anticancer Research. 2014 ; Vol. 34, No. 10. pp. 5241-5250.
@article{685bbe334340477cbb5e02262ac65e5e,
title = "Pharmacogenomics in lung cancer chemotherapy: A review of what the oncologist should know",
abstract = "Lung cancer is the leading cause of cancer-related death around the world; the addition of chemotherapy to treatment of this disease has been shown to significantly increase progression-free survival and overall survival. Despite newer chemotherapies, it is important to personalize the care (treatment and dose) upon each single patient's susceptibility for controlling and reducing adverse side-effects, at best. The present review describes the current status of pharmacogenomics studies regarding germline DNA variants that may alter response and tolerability to chemotherapeutic agents used to treat lung cancer, including perspective studies.",
keywords = "Cisplatin, Gemcitabine, Lung cancer chemotherapy, Pemetrexed, Pharmacogenomic, Polymorphism patents, Taxanes, Vinorelbine",
author = "Chiara D'Antonio and Annalisa Milano and Riccardo Righini and Onesti, {Concetta Elisa} and Maria Bassanelli and Rosa Falcone and Ida Paris and Salvatore Lauro and Paolo Marchetti",
year = "2014",
month = "10",
day = "1",
language = "English",
volume = "34",
pages = "5241--5250",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "10",

}

TY - JOUR

T1 - Pharmacogenomics in lung cancer chemotherapy

T2 - A review of what the oncologist should know

AU - D'Antonio, Chiara

AU - Milano, Annalisa

AU - Righini, Riccardo

AU - Onesti, Concetta Elisa

AU - Bassanelli, Maria

AU - Falcone, Rosa

AU - Paris, Ida

AU - Lauro, Salvatore

AU - Marchetti, Paolo

PY - 2014/10/1

Y1 - 2014/10/1

N2 - Lung cancer is the leading cause of cancer-related death around the world; the addition of chemotherapy to treatment of this disease has been shown to significantly increase progression-free survival and overall survival. Despite newer chemotherapies, it is important to personalize the care (treatment and dose) upon each single patient's susceptibility for controlling and reducing adverse side-effects, at best. The present review describes the current status of pharmacogenomics studies regarding germline DNA variants that may alter response and tolerability to chemotherapeutic agents used to treat lung cancer, including perspective studies.

AB - Lung cancer is the leading cause of cancer-related death around the world; the addition of chemotherapy to treatment of this disease has been shown to significantly increase progression-free survival and overall survival. Despite newer chemotherapies, it is important to personalize the care (treatment and dose) upon each single patient's susceptibility for controlling and reducing adverse side-effects, at best. The present review describes the current status of pharmacogenomics studies regarding germline DNA variants that may alter response and tolerability to chemotherapeutic agents used to treat lung cancer, including perspective studies.

KW - Cisplatin

KW - Gemcitabine

KW - Lung cancer chemotherapy

KW - Pemetrexed

KW - Pharmacogenomic

KW - Polymorphism patents

KW - Taxanes

KW - Vinorelbine

UR - http://www.scopus.com/inward/record.url?scp=84917691462&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84917691462&partnerID=8YFLogxK

M3 - Article

VL - 34

SP - 5241

EP - 5250

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 10

ER -